Drug class profile · refreshed daily from federal data

Antifibrinolytic Agent

2 molecules in this class, $7.8M combined CY2024 Part D spend across 112K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Antifibrinolytic Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $7.8Mcombined across class
Total Rx claims: 112K85K unique beneficiaries
Generic mfrs (active): 38across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tranexamic Acid

Brand: Cyklokapron · 108K Part D claims (CY24) · 83K beneficiaries · First FDA approval: 1986-12-30

23 generic mfrs 0 plans require PA

Low NADAC$0.360

→

Avg plan cost$0.548

Part D spend $4.8M 2× spread, current vs floor

Class share

61%

of class CY24 spend

View profile →

Aminocaproic Acid

4K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 1990-09-30

15 generic mfrs

Low NADAC$0.709

→

Avg plan cost$3.06

Part D spend $3.0M 4× spread, current vs floor

Class share

39%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.